Metabolic approaches: GLP-1 Incretins (semaglutide): appetite suppression | GLP-1/GIP incretins (tirzepatide): dual hormonal agonism | 5-Amino-1MQ: NNMT enzyme inhibition a non-hormonal mechanism, directly targeting lipid and NAD+ metabolism
5-Amino-1MQ is a small, non-hormonal molecule that targets lipid metabolism via NNMT inhibition and NAD+ preservation, without affecting appetite
Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604
These formulations often contain additional ingredients such as stabilizers, binders, fillers, carrier solutions, or excipients that support the final product format
Semaglutide users usually begin experiencing appetite suppression within the first 1 to 2 weeks, with meaningful weight loss becoming visible by weeks 4 to 8 and continuing to progress over the following months
